The practice management software integrates seamlessly with Advanced Scheduling which will give Carol County Gastroenterology the ability to maximize efficiency while improving patient care and satisfaction. Dr. Bowens staff will be able to modify Benchmarks comprehensive scheduling options to fit their individual practice dynamics and make the most of their critical assets. Benchmark is committed to delivering the most advanced software and services in the industry. We are extremely excited to be partnering with Carroll County Gastroenterology for years to come, stated Ernie Chastain, Vice-President of Benchmark Systems, We also look forward to providing the same reliable support to other healthcare providers in the state of New Hampshire. About Carroll County Gastroenterology Carroll County Gastroenterology Center has been offering a wide range of therapeutic and diagnostic services in Wolfeboro, New Hampshire since 1999. Dr. Michael R. Bowen, who is board-certified in both Internal Medicine and Gastroenterology, treats patients with a wide range of digestive symptoms and disorders. Carroll County Gastroenterology also offers a licensed Ambulatory Surgical Center providing professional care such as colonoscopies, upper endoscopies, liver biopsys and infusion therapies. For additional information go online to http://www.cc-gi.com. About Benchmark Systems Inc. Benchmark is a leading Internet based provider of fully integrated solutions that automates all of the clinical and business functions required for healthcare providers. Benchmark offers seamless integrated Patient Portals, Personal Health Records, Scheduling, EMR, Billing, Messaging, Fax, CPOE, Rx Scripting, and Revenue Cycle Management at an affordable monthly fee.
Association Between Thiopurine Use and Nonmelanoma Skin Cancers in Patients With Inflammatory Bowel Disease: A Meta-Analysis
E-mail: email@example.com Received 13March2013; Accepted 5November2013 Advance online publication 14January2014 OBJECTIVES: Thiopurines are the mainstay of treatment for patients with inflammatory bowel disease (IBD). Thiopurine therapy increases the risk of nonmelanoma skin cancers (NMSCs) in organ transplant patients. The data on NMSC in patients with IBD on thiopurines is conflicting. METHODS: We searched electronic databases for full journal articles reporting on the risk of developing NMSC in patients with IBD on thiopurine and hand searched the reference lists of all retrieved articles. Pooled adjusted hazard ratios and 95% confidence intervals (CIs) were determined using a random-effects model. Publication bias was assessed using Funnel plots and Egger’s test. Heterogeneity was assessed using Cochran’s Q and the I2 statistic. RESULTS: Eight studies involving 60,351 patients provided data on the risk of developing NMSC in patients with IBD on thiopurines. The pooled adjusted hazards ratio of developing NMSC after exposure to thiopurines in patients with IBD was 2.28 (95% CI: 1.50 to 3.45). There was significant heterogeneity (I2=76%) between the studies but no evidence of publication bias. Meta regression analysis suggested that the population studied (hospital-based vs. population-based) and duration of follow-up contributed significantly to heterogeneity. Grouping studies based on population studied and duration showed higher hazard rations in hospital-based and shorter duration studies. CONCLUSIONS: The risk of developing NMSC in patients with IBD on thiopurines is only modestly elevated.
why not try these out http://www.nature.com/ajg/journal/vaop/ncurrent/abs/ajg2013451a.html